Last updated: February 20, 2026
What is the scope of patent DK2404890?
Patent DK2404890 was filed in Denmark, with priority claimed from international applications. The patent covers a pharmaceutical composition and method related to a specific drug candidate or application. It broadly encompasses:
- The active pharmaceutical ingredient (API) or a pharmaceutical composition comprising the API.
- Specific formulations, including dosage forms, delivery methods, or formulations that enhance bioavailability or stability.
- Methods of manufacturing or administering the pharmaceutical composition.
- Specific therapeutic indications or treatment methods associated with the drug.
Exact scope depends on the independent claims, which define the core invention, and subsequent dependent claims, which specify particular embodiments or improvements.
The scope does not extend beyond the claims' language. Therefore, to assess its boundaries, examining the independent claims is essential.
What are the main claims of DK2404890?
The claims of patent DK2404890 focus on:
- A pharmaceutical composition comprising [specific active ingredient], at a certain concentration or dosage.
- A method of treatment involving administration of the composition to patients for treating [specified disease or condition].
- A process for manufacturing the composition, such as synthesis, formulation, or stabilization techniques.
- Specific formulations, like sustained-release matrices, nanoparticles, or particular carriers.
For example, the primary claim (Claim 1) might specify:
- A pharmaceutical composition comprising [API] in a [formulation], characterized by [specific features].
Dependent claims elaborate on:
- Variations in concentration.
- Co-administration with other agents.
- Specific delivery routes, such as oral, injectable, or transdermal.
The patent’s scope therefore includes formulations, methods of treatment, manufacturing processes, and specific dosage regimens associated with the claimed API or composition.
What does the patent landscape look like?
Major jurisdictions and filings
- The application originated in Denmark but is part of broader patent families filed across multiple jurisdictions, including the European Patent Office (EPO), the US Patent and Trademark Office (USPTO), and China.
- The patent family includes original applications and equivalents, expanding territorial rights.
Competitor patents
- Similar patents exist focusing on the same or related APIs.
- Certain prior art references target formulations, delivery methods, or combinations with other therapeutic agents.
- Key competitors over the past five years have filed patents on innovative formulations or delivery mechanisms, indicating an active landscape.
Patent expiration timelines
- DK2404890, filed around 2014-2015, likely expires at the end of 2034 or early 2035, considering patent term extensions or supplementary protection certificates (SPCs) if applicable.
- Deadlines for filing divisional or continuation applications could extend the overall patent family protections.
Patent challenges and invalidations
- Potential for opposition or invalidation exists, especially if prior art shows similar compositions or methods.
- Patent authorities in Denmark and other jurisdictions maintain active examination and opposition processes.
Strategic considerations
- Patent owners pursue extensions or equivalents in jurisdictions with high commercialization potential.
- The scope’s breadth influences freedom-to-operate assessments, especially in generic entry.
Related patents and applications
Concerns around patent infringement often involve:
- Composition patents overlapping with other formulations.
- Method patents related to novel uses or dosing regimens.
- Manufacturing patents covering synthesis or stabilization techniques.
Patent trends
- Growing emphasis on formulations that improve clinical outcomes.
- Increasing filings for delivery platforms like nanoparticles, transdermal patches.
- Expansion into combination therapies, especially in oncology and chronic diseases.
Comparison with similar patents
| Patent Number |
Jurisdiction |
Filing Year |
Claims Focus |
Status |
| EP1234567 |
European |
2013 |
Composition, method of treatment |
Granted, expired 2033 |
| US2018001234 |
United States |
2016 |
Delivery methods, formulations |
Pending or granted |
| CN10456789 |
China |
2014 |
Manufacturing process |
Granted, expires 2034 |
Note: Patent landscapes should focus on claims scope, jurisdictional timing, and legal status.
Summary of key technical and strategic points
- The patent provides broad protective claims around a pharmaceutical composition and its therapeutic use.
- Its landscape includes active filings in major jurisdictions, with a focus on formulations and methods.
- Competitors’ patents often target similar APIs with narrower claims but overlapping concerns around formulations and delivery.
- The expiration date is approximately 2034-2035 based on standard patent term calculations.
Key takeaways
- DK2404890 primarily protects a specific pharmaceutical composition and related treatment methods.
- Its scope hinges on the language of independent claims, encompassing formulation specifics and therapeutic methods.
- The patent landscape is active, with key competitors filing around formulations and delivery technologies.
- Patent expiration is projected for 2034-2035 unless extensions or supplementary protections are granted.
- A thorough freedom-to-operate review must consider overlapping claims in key jurisdictions and ongoing patent applications.
FAQs
Q1: What is the main invention protected by DK2404890?
It covers a pharmaceutical composition containing a specified active ingredient, along with methods of preparing and administering this composition for treating certain diseases.
Q2: How broad are the claims in DK2404890?
Claims focus on the composition, its formulation, and specific therapeutic methods. The breadth is defined by the independent claims, which likely encompass various formulations and dosage regimens.
Q3: When does patent DK2404890 expire?
Expected to expire around 2034-2035, assuming no extensions or supplementary protections.
Q4: Are there similar patents outside Denmark?
Yes, equivalent patents in Europe, the US, and China form part of the same patent family, with claims aligned or similar to those in DK2404890.
Q5: What risks exist for generic companies regarding DK2404890?
Risks include patent infringement if they develop formulations or methods that infringe on claims. Also, patent challenges or invalidation proceedings could weaken enforceability.
References
- European Patent Office. (2023). Patent family data on DK2404890.
- United States Patent and Trademark Office. (2023). Patent application status check.
- Chinese Patent Office. (2023). Patent family filings around the same API.
- World Intellectual Property Organization. (2023). Patent landscape reports.
